Premium
Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ 9 ‐THCV in animal models of Parkinson's disease
Author(s) -
García C,
PalomoGaro C,
GarcíaArencibia M,
Ramos JA,
Pertwee RG,
FernándezRuiz J
Publication year - 2011
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2011.01278.x
Subject(s) - substantia nigra , neuroprotection , pharmacology , receptor , tyrosine hydroxylase , agonist , hydroxydopamine , cannabidiol , neurodegeneration , parkinson's disease , chemistry , cannabinoid , endocrinology , medicine , dopamine , disease , cannabis , psychiatry
Previous findings have indicated that a cannabinoid, such as Δ(9)-THCV, which has antioxidant properties and the ability to activate CB(2) receptors but to block CB(1) , might be a promising therapy for alleviating symptoms and delaying neurodegeneration in Parkinson's disease (PD).